NASDAQ:CLSD
Clearside BioMedical, Inc Stock News
$1.33
+0.0200 (+1.53%)
At Close: May 20, 2024
Clearside Biomedical Inc (CLSD) Reports Q1 Loss, Tops Revenue Estimates
12:45pm, Friday, 08'th May 2020
Clearside Biomedical Inc (CLSD) delivered earnings and revenue surprises of 22.22% and 2.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock
Clearside Biomedical Announces First Quarter 2020 Financial Results
11:05am, Friday, 08'th May 2020
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, tod
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
04:30pm, Wednesday, 06'th May 2020
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teva's Patent Win, And Other News: The Good, Bad And Ugly Of Biopharma
08:56am, Thursday, 30'th Apr 2020
Teva achieves another patent lawsuit victory. Merck's Keytruda gets another approval. Clearside's NDA submission is delayed.
Clearside Biomedical (CLSD) Gets a Hold Rating from Needham
06:24pm, Tuesday, 28'th Apr 2020
Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD) today. The company's shares closed last Tuesday at $1.98. According
Clearside Biomedical (CLSD) Gets a Hold Rating from Needham
06:24pm, Tuesday, 28'th Apr 2020
Needham analyst
Serge Belanger
maintained a
Hold
rating on Clearside Biomedical (
CLSD
–
Research Report
) today. The company’s shares closed last Tuesday at $1.98.
According to
TipRanks.com
, Bel
Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health
11:05am, Tuesday, 28'th Apr 2020
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, ann
Clearside Biomedical appoints Nancy Hutson to board of directors CLSD;PFE
11:46am, Wednesday, 22'nd Apr 2020
Clearside Biomedical appoints Nancy Hutson to board of directors CLSD PFE
Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors
11:05am, Wednesday, 22'nd Apr 2020
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, ann
Needham Sticks to Its Hold Rating for Clearside Biomedical (CLSD)
09:38am, Thursday, 16'th Apr 2020
Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD) today. The company's shares closed last Wednesday at $2.41.
Needham Sticks to Its Hold Rating for Clearside Biomedical (CLSD)
09:38am, Thursday, 16'th Apr 2020
Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD – Research Report) today. The company’s shares closed
Clearside Biomedical Establishes Scientific Advisory Board with Distinguished Retinal Physicians
11:05am, Thursday, 09'th Apr 2020
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, ann
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
11:05am, Wednesday, 08'th Apr 2020
ALPHARETTA, Ga., April 08, 2020 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and.
The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
04:10pm, Sunday, 29'th Mar 2020
After starting the week ended March 28 on the backfoot, biotech stocks recovered through the week. Activity in the space remained light, although coronavirus (COVID-19) news flow continued to dominate
CCL, EXPE among premarket losers
01:25pm, Thursday, 12'th Mar 2020
ZAGG (NASDAQ:ZAGG) -44% after ending strategic review with no deal and Q4 earnings.Sasol (NYSE:SSL) -37%.Party City Holdco (NYSE:PRTY) -36% on Q4 earnings.Norwegian Cruise Line Holdings (NYSE:NCLH
